Santhera is a Swiss specialty pharmaceutical company focused on the development and commercialisation of therapies for rare diseases with high unmet medical need. Its lead product, AGAMREE (vamorolone), is an approved treatment for Duchenne muscular dystrophy and is being rolled out globally through a combination of direct commercialisation and strategic licensing partnerships.
Healthcare |
Comment
Dario Eklund
CEO
Catherine Isted
CFO
thematic
Consumer
thematic
Energy & Resources